Tubulin Polymerization-IN-2 is a powerful anticancer agent that targets β-tubulin, exhibiting an IC 50 of 0.92 μM. It demonstrates promising efficacy against a range of cancer cell lines including leukemia, non-small cell lung, renal, prostate, and breast cancers [1].

Tubulin polymerization-IN-2 (compound 2b) exhibits potent anti-cancer properties, effectively targeting epidermal carcinoma and breast carcinoma with IC50 values of 2.3 μM (KB) and 2.2 μM (BT-549), respectively [1]. At 0.342 μM over 24 hours, it disrupts DNA synthesis or repair, causes S phase arrest in MCF-7 cells, and induces apoptosis by reducing Bax, APAF-1, and caspase-3 expression while increasing BCL-2 mRNA levels [1]. It also significantly inhibits β-tubulin polymerization with a K_i value of 0.09 μM at concentrations of 0.01 to 10 μM over one hour [1].